Fig. 7

In vivo assessment of HER2-targeted and adaptive tumor-infiltrating lymphocyte (TIL) therapy strategies. a PDX tumors of patient CAT061 were treated with neratinib and TIL combination strategy, neratinib or TIL. b PDX tumor size of these mice was shown (left graph), and the weights of PDX tumors (day 28) were shown (right graph). c Granzyme B (GrzB) expression in CD4⁺ T cells was determined by flow cytometry (Student’s t-test). d Multiplex immunofluorescent images of CD4 and GrzB positive cells in the tumor tissue of TIL and TIL combined neratinib treatment groups. e Representative hematoxylin and eosin-stained sections and immunohistochemistry images of Ki67 staining of tumors from each of the treatment groups (scale bar, 50 μm). f Quantitation of the Ki67 staining in the tumors of the treatment groups. ^*p < 0.05, ^**p < 0.01, ^***p < 0.005, NS, not significant